Novo Nordisk, the Danish pharmaceutical company responsible for the widely recognised weight-loss medications Ozempic and Wegovy, has initiated legal proceedings against its primary competitor, Eli Lilly. The lawsuit, filed in the US this week, accuses Eli Lilly of engaging in false advertising practices. Novo Nordisk claims that Eli Lilly's promotional campaigns for its own weight-loss drugs, Mounjaro and Zepbound, are designed to create a misleading impression that its products are more effective, particularly by comparing the highest approved doses of its medicines with lower, and in some cases, older doses of Novo Nordisk's offerings, while allegedly omitting newer, higher-dose options that are now available.
According to Novo Nordisk, Eli Lilly's nationwide advertising campaigns constitute "multiple violations" of federal and state false advertising and unfair competition laws. The company alleges that Eli Lilly has intentionally selected outdated studies to compare its highest doses against lower doses of Novo Nordisk's medicines, thereby deceptively presenting its products as superior. Novo Nordisk stated that these advertisements either bury or omit "critical clinical context" that would provide a more accurate comparison. The specific products cited in the alleged incorrect comparisons are Mounjaro versus Ozempic, and Zepbound versus Wegovy.
The legal challenge underscores the fierce competition dominating the rapidly expanding global market for weight-loss drugs. Analysts have projected this market, particularly in the US, could exceed a value of £80 billion by 2030, reflecting the significant demand and potential for pharmaceutical companies. Both Novo Nordisk and Eli Lilly are vying for market leadership, with their respective products showing considerable efficacy in managing obesity and type-2 diabetes, leading to substantial revenue growth for both firms.
John F. Kuckelman, senior vice president and group general counsel for Novo Nordisk, emphasised the importance of accurate information for patients. He stated, "As new and more effective treatment options become available, people deserve accurate information that reflects the latest scientific evidence and helps them make informed care decisions." Kuckelman added that healthcare companies have a responsibility to ensure their public claims are accurate and current, asserting that "ineffective, fine-print disclaimers do not fix the misleading impression created by major national campaigns."
Novo Nordisk is seeking a court order that would compel Eli Lilly to withdraw its current advertising materials and, crucially, implement a "corrective advertising campaign." The company has indicated that if Eli Lilly does not voluntarily remove the disputed commercials, it intends to file a motion in the coming days to seek a preliminary injunction, which would legally block their broadcast. This legal battle could have broader implications for how pharmaceutical companies market their products, potentially setting precedents for advertising standards in a highly lucrative and competitive sector.